Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14277510 | 1.00 | KIF11 (0.73) | KIF11KCNH2 | |
| SCHEMBL14302059 | 1.00 | KIF11 (0.73) | KIF11KCNH2 | |
| SCHEMBL4689954 | 0.87 | KIF11 (0.73) | KIF11KCNH2 | |
| SCHEMBL4060252 | 0.85 | KIF11 (1.00) | KIF11KCNH2 | |
| SCHEMBL4059774 | 0.85 | KIF11 (1.00) | KIF11KCNH2 | |
| SCHEMBL4788684 | 0.85 | KIF11 (0.56) | KIF11KCNH2 | |
| SCHEMBL4059946 | 0.84 | KIF11 (1.00) | KIF11KCNH2 | |
| SCHEMBL4689759 | 0.83 | KIF11 (0.72) | KIF11KCNH2 | |
| SCHEMBL4059323 | 0.81 | KIF11 (0.90) | KIF11KCNH2 | |
| SCHEMBL5104270 | 0.79 | KIF11 (0.71) | KIF11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1636182-A4 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-09-03 | — | — | EP | claimed |
| EP-1636182-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111193-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | claimed |
| EP-1636182-A4 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-7329762-B2 | Prodrugs of mitotic kinesin inhibitors | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20060135594-A1 | Prodrugs of mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-06-22 | — | — | US | disclosed |
| EP-1636182-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111193-A2 | PRODRUGS OF MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135594-A1 | Prodrugs of mitotic kinesin inhibitors | KIF2C, KIF5B, KIFC1 | KIF11 11/4885KCNH2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.